Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients

PURPOSE: UGT1A1*28 confers a higher risk of toxicity in patients treated with irinotecan. Patients with *1/*1 and *1/*28 genotypes might tolerate higher than standard doses of irinotecan. We aimed to identify the maximum tolerated dose (MTD) of irinotecan in mCRC patients with *1/*1 and *1/*28 genot...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Toffoli, Giuseppe, Sharma, Manish R., Marangon, Elena, Posocco, Bianca, Gray, Elizabeth, Mai, Quan, Buonadonna, Angela, Polite, Blase N., Miolo, Gianmaria, Tabaro, Gianna, Innocenti, Federico
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777349/
https://ncbi.nlm.nih.gov/pubmed/27507617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1012
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料